No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 19 of the 40 quarters in the window, leaving 21 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 783.0x · 10Y median 242.1x · 79th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:03.462Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Creative Medical Technology Holdings, Inc. (CELZ) stock was $0.91 as of Oct 6, 2026, 10:03 AM EDT, down 1.07% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -71.4% · 3-year avg -42.9%/yr · 5-year avg -58.0%/yr
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology.
Biotechnology · Phoenix, AZ
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.24
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.41
vs Estimate
$-0.39
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CELZ | $2.35M | $0.91 | -1.07% | -71.43% | -57.96% | -72.19% | N/A |
| 2ITOC | $2.38M | $0.25 | +1.85% | N/A | N/A | N/A | vs CELZ |
| 3FBLG | $2.43M | $1.16 | -1.65% | -89.14% | N/A | N/A | vs CELZ |
| 4MBRX | $2.51M | $0.47 | -1.43% | -95.81% | -78.48% | -64.00% | vs CELZ |
| 5ISPC | $2.60M | $1.03 | -1.74% | -97.66% | -81.14% | N/A | vs CELZ |
| 6GOVX | $2.07M | $0.28 | -12.38% | N/A | N/A | N/A | vs CELZ |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$20.00
+2097.3% upside
Low
$20.00
Current
$0.91
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Quarter ending Dec 2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.18 | $-1.18 | $-1.18 | 1 |
| FY 2027 | $-0.88 | $-0.88 | $-0.88 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $23.41M | $23.41M | $23.41M | 1 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $33.83M |
| $33.83M |
| $33.83M |
| 1 |
